Advances in Therapy,
Год журнала:
2023,
Номер
40(8), С. 3281 - 3290
Опубликована: Июнь 14, 2023
This
article
has
been
co-authored
by
a
patient
with
right-sided
BRAFV600E
metastatic
colorectal
cancer
(mCRC),
his
caregiver,
and
an
oncologist.
Here
the
caregiver
discuss
their
personal
experiences
struggling
cancer,
including
fears,
expectations,
attitudes
as
disease
progresses.
The
oncologist
describes
how
patients
mCRC
are
treated
management
strategy
can
be
balanced
to
mitigate
any
side
effects.
Improved
diagnostic
techniques
availability
of
numerous
treatment
options,
various
chemotherapy
schemes
molecular-targeted
drugs,
aid
rapid
implementation
algorithms.
pivotal
roles
patients'
associations
in
general
support
those
close
them,
facilitating
link
healthcare
professionals,
highlighted
this
perspective
piece.This
French
since
December
2020,
oncologist,
physician
currently
based
at
Institut
Paoli-Calmettes
Marseille.
Metastatic
is
characterized
high
number
genetic
mutations,
each
being
associated
different
prognosis
response
treatment.
Around
8–12%
will
present
BRAF
mutation
tumour,
majority
which
V600E,
leading
poor
standard
short
overall
survival.
fears
receiving
immunotherapy
fifth
line
treatment,
while
actively
communicates
patients’
understand
more
about
identify
new
possibilities.
lines
received
did
not
follow
usual
algorithms
proposed
France
for
BRAFV600E-mutated
cancer.
sought
clinical
trial
patient’s
third-line
from
information
provided
associations.
Thus,
play
key
role
professionals.
IntechOpen eBooks,
Год журнала:
2024,
Номер
unknown
Опубликована: Фев. 14, 2024
This
review
highlights
the
most
promising
biomarker
tests
of
tumor
tissue
from
colonoscopy
biopsy
for
more
individualized
therapeutic
approaches
to
patients
with
colorectal
carcinoma
(CRC).
Biomarkers
are
a
key
tool
in
early
detection,
survival,
and
predicting
treatment
response
prognostic
value.
The
can
help
doctors
select
specific
CRC
targeted
therapy.
is
third
common
cancer
diagnosed,
second
leading
cause
cancer-related
deaths
worldwide,
despite
progress
made
detection
management
through
surgery,
chemotherapy,
radiotherapy,
immunotherapy.
With
population
totaling
273,523,621
people,
Indonesia
has
estimated
396,914
new
cases
all
234,511
deaths.
Among
those
cases,
34,189
17,786
occurred
2020.
Most
were
located
rectum
compared
distal
colon
or
proximal
colon.
heterogeneous
cancer.
Its
vary,
depending
on
location
(proximal,
colon,
rectum),
clinical
signs
symptoms,
staging
biomarkers
such
as
KRAS
NRAS,
BRAF
V600E,
MSI
high
(dMMR),
CIN,
HER2-amplified,
PD-1,
CTLA-4,
MEK,
NTRK
gene
fusion-positive.
CSCs
other
being
developed
remain
under
investigation.
Abstract
Objectives
The
objective
of
this
study
was
to
evaluate
the
predictive
value
18
F-fluorodeoxyglucose
[
F]FDG
positron
emission
tomography
(PET-CT)
radiomic
parameters
in
relation
KRAS/BRAF/EGFR
mutations
patients
with
metastatic
colorectal
cancer
(mCRC).
Methods
Blood
samples
were
collected
from
90
mCRC
assess
KRAS
G13V,
BRAF
V600E,
and
EGFR
exon
20
mutations.
PET-CT
scans
performed,
parameters,
including
SUV
max,
max
TBR,
total
MTV,
TLG,
calculated
correlated
different
genotypes
haplotypes
aforementioned
Results
TBR
significantly
greater
G13V
V600E
than
wild-type
genotype.
SUVmax
also
Haplotype
analysis
revealed
that
other
patients,
a
specificity
68.18%
sensitivity
65.28%.
Conclusion
results
suggest
F]
FDG
particularly
have
potential
serve
as
noninvasive
tools
for
predicting
mutation
status
patients.
Journal of Personalized Medicine,
Год журнала:
2023,
Номер
13(7), С. 1051 - 1051
Опубликована: Июнь 26, 2023
KRAS
mutation
in
tumor
tissue
is
a
well-known
predictor
of
resistance
to
the
treatment
anti-EGFR
antibodies
metastatic
colorectal
cancers
(mCRC).
However,
prognostic
value
low-frequency
plasma
circulating
DNA
(ctDNA)
predicting
pretreated
mCRC
patients
remains
controversial.
This
study
retrospectively
reviewed
clinical
course,
including
response
and
anti-VEGF
therapies,
changes
serum
marker
levels
along
with
image
studies
<1.5%
mutations
detected
ctDNA
by
next-generation
sequencing
(NGS)
at
single
center
Taiwan.
We
identified
six
G12V/G12D/G12S/G13D
(variant
allele
frequency
0.26~1.23%)
ctDNA.
Co-occurring
APC,
TP53,
MAP2K1,
KEAP1,
or
CTNNB1
were
also
detected.
Although
all
had
adjustments
within
one
month
after
genetic
test,
image-evident
progression
was
noted
median
4
months
afterwards.
Re-challenge
therapy
combination
anti-EGFR,
anti-VEGF,
FOLFIRI
chemotherapy
found
be
ineffective
patient
0.38%
G12D
baseline
Our
suggests
that
detection
could
used
as
patients.
Advances in Therapy,
Год журнала:
2023,
Номер
40(8), С. 3281 - 3290
Опубликована: Июнь 14, 2023
This
article
has
been
co-authored
by
a
patient
with
right-sided
BRAFV600E
metastatic
colorectal
cancer
(mCRC),
his
caregiver,
and
an
oncologist.
Here
the
caregiver
discuss
their
personal
experiences
struggling
cancer,
including
fears,
expectations,
attitudes
as
disease
progresses.
The
oncologist
describes
how
patients
mCRC
are
treated
management
strategy
can
be
balanced
to
mitigate
any
side
effects.
Improved
diagnostic
techniques
availability
of
numerous
treatment
options,
various
chemotherapy
schemes
molecular-targeted
drugs,
aid
rapid
implementation
algorithms.
pivotal
roles
patients'
associations
in
general
support
those
close
them,
facilitating
link
healthcare
professionals,
highlighted
this
perspective
piece.This
French
since
December
2020,
oncologist,
physician
currently
based
at
Institut
Paoli-Calmettes
Marseille.
Metastatic
is
characterized
high
number
genetic
mutations,
each
being
associated
different
prognosis
response
treatment.
Around
8–12%
will
present
BRAF
mutation
tumour,
majority
which
V600E,
leading
poor
standard
short
overall
survival.
fears
receiving
immunotherapy
fifth
line
treatment,
while
actively
communicates
patients’
understand
more
about
identify
new
possibilities.
lines
received
did
not
follow
usual
algorithms
proposed
France
for
BRAFV600E-mutated
cancer.
sought
clinical
trial
patient’s
third-line
from
information
provided
associations.
Thus,
play
key
role
professionals.
